Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity.

@article{Hamel2008SuppressionOP,
  title={Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity.},
  author={Keith M. Hamel and Paul D. Doodes and Yanxia Cao and Yumei Wang and Jeffrey D. Martinson and Robert Dunn and Marilyn R. Kehry and B{\'a}lint Farkas and Alison Finnegan},
  journal={Journal of immunology},
  year={2008},
  volume={180 7},
  pages={4994-5003}
}
B cells have been implicated in the pathogenesis of rheumatoid arthritis (RA) since the discovery of RA as an autoimmune disease. There is renewed interest in B cells in RA based on the clinical efficacy of B cell depletion therapy in RA patients. Although, reduced titers of rheumatoid factor and anti-cyclic citrullinated peptide Abs are recorded, the mechanisms that convey clinical improvement are incompletely understood. In the proteoglycan-induced arthritis (PGIA) mouse model of RA, we… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…